Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis
Public ClinicalTrials.gov record NCT05975983. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this revised Phase IIa study is to demonstrate safety of INS018\_055 over 12 weeks in adults with Idiopathic Pulmonary Fibrosis (IPF).
Study identification
- NCT ID
- NCT05975983
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 40 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 40 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 8, 2024 (Actual)
- Primary completion
- Feb 28, 2026 (Estimated)
- Completion
- Feb 28, 2026 (Estimated)
- Last update posted
- Nov 12, 2025
2024 – 2026
United States locations
- U.S. sites
- 12
- U.S. states
- 9
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham | Birmingham | Alabama | 35294 | Recruiting |
| HonorHealth Research Institute | Scottsdale | Arizona | 85258 | Recruiting |
| Keck School of Medicine of USC | Los Angeles | California | 90033 | Recruiting |
| Florida Lung Asthma and Sleep Specialist | Celebration | Florida | 34747-1818 | Recruiting |
| Central Florida Pulmonary Group, P.A. (CFPG) - Downtown Orlando | Orlando | Florida | 32803-5727 | Recruiting |
| Southeastern Research Center | Winston-Salem | North Carolina | 27103-4007 | Recruiting |
| University of Oklahoma Health Sciences Center (OUHSC) | Oklahoma City | Oklahoma | 73104-5417 | Recruiting |
| Temple University Hospital-Temple Lung Center | Philadelphia | Pennsylvania | 19140 | Recruiting |
| Bogan Sleep Consultants, LLC | Columbia | South Carolina | 29201-2953 | Recruiting |
| University of Texas Southwestern Medical Center | Dallas | Texas | 75235-6243 | Recruiting |
| Metroplex Pulmonary and Sleep Center | McKinney | Texas | 75069-1898 | Recruiting |
| Research Centers of America | McKinney | Texas | 75071 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05975983, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 12, 2025 · Synced Nov 9, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05975983 live on ClinicalTrials.gov.